AAM
CTIC

Azzad Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Azzad Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,770
Closed -$28.7K – 268
2013
Q3 		$28.7K Hold
1,770
– – 0.02% 230
2013
Q2 		$28.7K Buy
+1,770
New +$20.7K 0.02% 227

Other funds holding CTIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Azzad Asset Management's CTIC Position: Q4 2013 in Review

Azzad Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2013, closing a stake of 1,770 shares — an estimated $28.7K sold.

Azzad Asset Management first reported a position in CTIC in Q2 2013 and held it in 2 quarters. The position peaked at $28.7K in Q3 2013. 76 funds tracked by Wall St. Rank hold CTIC as of Q4 2013.

  • Azzad Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2013 after selling out during the quarter.
  • Azzad Asset Management sold 1,770 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2013, an estimated $28.7K.
  • Azzad Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 2 quarters.
  • Azzad Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $28.7K in Q3 2013.
  • 76 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2013.

Based on Azzad Asset Management's 13F filing for Q4 2013, filed 3 Apr 2024.